Bioverativ Inc. (NASDAQ:BIVV) Files An 8-K Results of Operations and Financial Condition

ME Staff 8-k
-
0

Bioverativ Inc. (NASDAQ:BIVV) Files An 8-K Results of Operations and Financial Condition
Item 2.02    Results of Operations and Financial Condition.

On May 3, 2017, Bioverativ Inc. issued a press release announcing its results of operations and financial condition for the first quarter ended March 31, 2017. A copy of the press release is furnished as Exhibit 99.1 and is incorporated herein by reference.

The press release is being furnished to Item 2.02 of this Current Report on Form 8-K and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that Section, nor shall such document be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act.

Item 9.01    Financial Statements and Exhibits.

The exhibit listed on the Exhibit Index immediately preceding such exhibit is furnished as part of this Current Report on Form 8-K.


About Bioverativ Inc. (NASDAQ:BIVV)

Bioverativ Inc. (Bioverativ) is a biotechnology company. The Company is focused on the discovery, research, development and commercialization of therapies for the treatment of hemophilia and other blood disorders. It markets approximately two products, including ELOCTATE [Antihemophilic Factor (Recombinant), Fc Fusion Protein], and ALPROLIX [Coagulation Factor IX (Recombinant), Fc Fusion Protein], extended half-life clotting-factor therapies for the treatment of hemophilia A and hemophilia B, respectively. ELOCTATE and ALPROLIX use a process known as Fc fusion to link recombinant factor VIII and factor IX, respectively, to a protein fragment in the body known as Fc. The fusion of the factor with the Fc protein fragment uses a naturally occurring pathway and is designed to extend the half-life of the factor thereby making the product last longer in a person’s blood than various factor therapies. Its pipeline includes BIVV 001(rFVIIIFc-VWF-XTEN) and BIVV 002 (rFIXFc-XTEN).

Bioverativ Inc. (NASDAQ:BIVV) Recent Trading Information

Bioverativ Inc. (NASDAQ:BIVV) closed its last trading session down -1.50 at 55.98 with 1,413,267 shares trading hands.